“In vitro” and “preclinical” are often treated as different levels of evidence. That creates a misleading picture of how peptide research is actually organized.

In vitro tells you where the experiment happened. Preclinical tells you where the research sits in relation to human clinical studies. An experiment performed in cells or another laboratory system outside an intact organism can therefore be part of a preclinical research program.

The FDA’s preclinical research framework includes in vitro and in vivo approaches within preclinical research, alongside newer non-animal methods.

Knowing which type of study you are reading helps you judge what the results can actually show. A cell experiment, an animal model, and a human trial answer different questions even when they investigate the same peptide.

This guide explains how in vitro, ex vivo, and in vivo research fit within the broader preclinical stage, what each approach can establish, and how to read peptide studies without giving the evidence more weight than the experimental design supports.

For a broader look at the field, the peptide therapy research overview covers different peptide classes and the biological pathways researchers study.

Is In Vitro Research Considered Preclinical Research?

Yes. In vitro studies can be part of preclinical research.

The NCI defines in vitro as research performed outside a living organism, such as experiments using isolated cells or other laboratory systems. Preclinical describes research conducted before human clinical studies.

So the two terms describe different things. In vitro identifies the experimental setting, while preclinical identifies the stage of research.

What Is the Difference Between In Vitro, Ex Vivo, In Vivo, and Preclinical Peptide Research?

In vitro, ex vivo, and in vivo describe where or how an experiment is performed, while preclinical describes the broader stage of research before human clinical studies.

Term	What it means	Typical peptide research	What it can show
In vitro	Outside an intact organism	Cell cultures, receptor assays, organoids	Molecular and cellular activity
Ex vivo	Removed tissue studied outside the organism	Tissue slices, isolated organs	Responses in more intact tissue systems
In vivo	Inside a living organism	Animal models	PK/PD, biodistribution, systemic effects, toxicology
Preclinical / nonclinical	Research before human trials	Can include in vitro, ex vivo, in vivo, and non-animal methods	Mechanism, exposure, pharmacology, toxicology
Clinical	Research in humans	Human trials and other clinical studies	Human pharmacology, safety, and efficacy

Ex vivo sits between standard cell culture and whole-organism research. It uses tissue or cells removed from an organism while preserving more of their original biological context.

Researchers do not always use the term exactly the same way, so the methods section of a study is more informative than the label alone.

How Does Peptide Research Progress From Laboratory Models to Human Studies?

Peptide research usually moves from simpler laboratory models to more complex biological systems, but the process is rarely a straight line.

Researchers may begin with computational models or in vitro assays to study target binding, signaling, potency, and stability. Those results can then guide work in ex vivo tissues or in vivo models that add circulation, metabolism, tissue exposure, and whole-organism effects.

Results often send researchers backward as well as forward. An unexpected animal finding may lead to new cell experiments to isolate the mechanism behind it, while a weak in vitro result may prompt another round of peptide design before any in vivo work begins.

BPC-157 provides a useful example. Its published research includes both cellular studies and animal models, while most of the evidence remains preclinical rather than clinical.

What Do In Vitro Peptide Studies Usually Measure?

In vitro peptide studies usually test specific molecular or cellular effects under controlled laboratory conditions.

Common measurements include:

• Receptor binding, which shows whether the peptide interacts with its intended receptor and how strongly
• Functional receptor activity, which shows whether that binding actually activates or blocks the expected signal
• Cell signaling, including changes in cAMP, calcium, phosphorylation, NF-κB, MAPK, or Akt/mTOR pathways
• Cell behavior, such as migration, proliferation, apoptosis, cytokine release, barrier function, or gene expression
• Peptide stability, which measures how quickly the compound breaks down in plasma, serum, enzymes, or other test systems
• Cellular uptake, which shows whether the peptide enters cells or remains outside them
• Concentration-response relationships, which show how the measured effect changes as peptide concentration increases or decreases

These experiments can establish what a peptide does in a defined biological system. They cannot show how circulation, metabolism, multiple organs, immune responses, or clearance will change that behavior in a living organism.

What Does In Vivo Preclinical Peptide Research Add?

In vivo research adds whole-organism biology that cell and tissue models cannot reproduce on their own.

Researchers can study how quickly a peptide enters and leaves circulation, where it travels, which tissues are exposed, how it is broken down, and how the body clears it. They can also examine systemic signaling, immune responses, organ toxicity, and interactions between multiple physiological systems.

This is where pharmacokinetics and pharmacodynamics become especially important. Pharmacokinetics describes what the organism does to the peptide, including absorption, distribution, metabolism, and clearance. Pharmacodynamics describes what the peptide does to the organism once it reaches its target.

A peptide that produces a strong effect in cultured cells may behave very differently once enzymes begin degrading it, tissues limit its distribution, or the immune system and other organs alter the response.

An in vivo model is not automatically more informative simply because it uses a living organism. The model still has to reproduce the biology researchers are trying to study closely enough to answer the question.

That is one reason research is expanding beyond the simple “cells first, animals second” model toward organoids, engineered tissues, computational systems, and other approaches designed to capture specific features of human biology more directly.

Does Preclinical Research Always Require Animal Studies?

No. Preclinical research can include animal studies, but it does not always require them.

The FDA is expanding its use of New Approach Methodologies, or NAMs. These include human-cell systems, organoids, organ-on-chip models, and computational approaches that can complement or replace certain animal studies.

Animal models still play an important role in many research programs, especially when researchers need to study whole-body effects such as metabolism, circulation, immune responses, or toxicity.

Other models can answer different questions more directly. An organoid, for example, can reproduce some features of human tissue biology that a standard cell culture cannot, while an organ-on-chip system can model interactions between cells, fluid flow, and tissue structure.

So “preclinical” does not tell you which model was used. You still need to look at the study design to see whether the evidence came from cells, tissues, animals, computational models, or a combination of them.

Why Do Research Suppliers Reference In Vitro Data in Their Listings?

Research suppliers often reference in vitro data because that may be the most developed evidence available for a newer or narrowly studied peptide.

A cell or biochemical study can show whether a peptide binds a receptor, changes a signaling pathway, affects gene expression, or produces another measurable molecular response. That can provide useful evidence about mechanism even when researchers have not yet characterized what happens in a whole organism.

The main limitation is scope.

A receptor-binding result can show that a peptide interacts with a target. It cannot tell you how quickly the peptide is broken down in the body, whether it reaches the relevant tissue, what systemic effects appear, or whether the same response occurs in humans.

So in vitro evidence should be read for what it actually demonstrates rather than treated as an early version of a clinical result.

The evidence also varies from peptide to peptide. Some compounds are supported mainly by cell and animal studies, while others have published human pharmacology data.

Check the evidence stage for the specific compound rather than assuming every “research peptide” sits at the same point in development.

How Should Researchers Interpret Preclinical Peptide Studies?

Researchers should judge a preclinical peptide study by how well it was designed, controlled, and reported, not by the headline result alone.

NIH guidance on preclinical research reporting highlights several things worth checking:

1. Model relevance: Why was this species, strain, disease model, injury model, or other experimental system chosen? The model should make biological sense for the question being studied.
2. Biological characteristics: Check the species, strain, sex, age, and health status of the subjects. These factors can influence the result.
3. Sample size: Look at how many animals or experimental units were included and whether the researchers explained why that number was sufficient.
4. Randomization: Random assignment helps reduce the chance that one group starts out systematically different from another.
5. Blinding: Researchers assessing the results should ideally not know which subjects received which treatment, especially when outcomes involve judgment.
6. Experimental exposure: Check the amount, route, schedule, and duration used in the study. These are study-design variables that help explain what was actually tested.
7. Controls: A useful study needs an appropriate comparison group, such as untreated subjects, a vehicle control, or an established active comparator.
8. Outcome relevance: Look at what was actually measured. A change in a biomarker, tissue sample, functional outcome, pharmacokinetic measure, or imaging result can answer very different questions.
9. Statistics: Effect sizes, uncertainty, exclusions, sample-size calculations, and statistical methods should be reported clearly enough to judge how convincing the result is.
10. Replication: Independent reproduction by another laboratory strengthens a finding, especially when the original and replicated studies both use strong controls and transparent methods.

Replication cannot rescue a weak experimental design. If the same poorly controlled experiment is repeated, the underlying limitations remain.

The most useful question is therefore not simply whether a peptide produced an effect. Look at how the effect was measured, what it was compared against, how large and consistent it was, and whether the study design gives researchers a good reason to trust it.

What Can Each Research Model Actually Establish?

Finding	In Vitro	In Vivo Preclinical	Human Clinical
Receptor binding	Yes	Can support	Can support
Cellular signaling	Yes	Yes	Sometimes measurable
Whole-body distribution	No	Yes	Yes
Pharmacokinetics	Limited, model-based	Yes	Yes
Organ-system interactions	No	Yes	Yes
Toxicity signals	Selected cellular toxicity only	Organ/system-level toxicity	Human adverse effects
Human efficacy	No	No	Yes
Human safety	No	No	Yes

Use the table to check whether a study actually supports the claim being made about it.

A cell study can support a molecular or cellular finding. An animal study can add whole-organism pharmacology. Neither should be written up as though it had already shown the same result in humans.

When human data does exist for a peptide, evaluate that evidence separately. It answers a different set of questions and should not be treated as a simple extension of the preclinical findings.

Review batch-specific research documentation in the COA library when comparing research peptide suppliers.

Frequently Asked Questions

This page describes general research methodology and terminology. It does not describe the properties, safety, or effects of any specific compound, and no therapeutic or efficacy claims are made.